1 / 45

Leukemias

Leukemias. Jan Żeromski Pathology 2010/2011. Definition and two main lineages. Malignant proliferation of white cells of the hematopoietic system with infestation of blood and usually bone marrow. Lymphoid and myeloid leukemias. Cell origin and pathogenesis.

marlo
Download Presentation

Leukemias

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Leukemias Jan Żeromski Pathology 2010/2011

  2. Definition and twomainlineages • Malignant proliferation of white cells of the hematopoietic system with infestation of blood and usually bone marrow. • Lymphoid and myeloid leukemias

  3. Cellorigin and pathogenesis • Hematopoieticstemcellsdifferentiating to progenitorones, eithermyeloidorlymphoidlineage • Chromosomalabnormalities, most commonlytranslocations, • Inheritedgeneticdefects (Down syndrome, Bloomsyndrome, ataxiatelangiectasia • Someviruses: Epstein-Barr (EBV), herpesvirus -8, HTVL-1 etc. • Environmentalfactors: chronicinfection, Helicobacterpylori, radiationtherapy, chemotherapy

  4. Classification of lymphoidleukemias • Precursorleukemias - acutelymphoblastic l. - pro B - pre B (common) • Peripheralones - chroniclymphocytic l. - prolymphocytic l. - hairycell l. - plasmacellmyeloma • Precursor leukemias - acute lymphoblastic l. • Peripheral ones (T and NK) - chronic lymphocytic l. - large granular lymphocytic l. - Sezary syndrome - NK-cell leukemia B-cell origin T-cell origin

  5. Significance of cellimmunophenotype • Definition:the set of differentiationantigensexpressed on a givencelltype • Lymphoid and myeloidcellsubsetsinvariousstages of maturationhavedistinctimmunophenotype • Differentiationantigensareclassifiedaccordingto clusterdeterminants (CD) system • CD classificationcoversmorethan 300 antigenicepitopessearched by monoclonalantibodies • Each leukemia typehascharacteristic set of CD markers, whatconstitutesnowadayscurrentclassificationhematopoieticmalignancies and thebasis of diagnosis

  6. B cell lineage antigens differentiation

  7. Clonality – generearrangement • Clonality – crucialdifferencebetweenneoplastic and normallymphocytes • Uniquefeature of lymphocytes – antigen receptor • Antigen receptor generearrangementdetermines antigenspecificity of lymphocytes • Rearrangementprecedesneoplastictransformation • Thusdaughtercellsfrommalignantcellprogenitorexpressthe same antigen receptor (either T or B) – form identicalcell clone

  8. Acute Lymphoblastic Leukemia • Most cases are Tdt positive • Most express CD10 (common ALL antigen) • Most are “pre-B cell” phenotype • 15-20% T-cell lineage • 5% B-cell phenotype

  9. Acute Lymphoblastic Leukemia

  10. General division of myeloidneoplams • Acute myelogenous leukemias (8 types) • Myelodysplastic syndromes (MDS) • Chronic myeloprolifeative disorders: - chronic myelogenous leukemia - polycythemia vera - essential thrombocytosis - primary meylofibrosis

  11. FAB classification of acutemyelogenousleukemias • M0 AML – non-differentiated, incidence 2-3% • M1 AML – almostwithoutdifferentiation, 20% • M2 AML – myeloidmaturation of granuloc.30-40% • M3 AML – hypergranularpromyelocytes, 5-10% • M4 AML – cells of bothmyelocytic (min.20%) and monocyticorigin (<30%), 15-20% • M5 AML – Monoblasts (M5a) and monocytes (M5b), 10% • M6 AML – dysplasticerythroidprecursors and myeloblasts, 5% • M7 megakaryocytic leukemia – blasts of megakaryoc.lineagepredominate, 1% Number of blastsinall: < 20%

  12. Myeloid cell lineage antigens differentiation

  13. Significance of geneticabnormalities • Chromosomaltranslocationisfairlycommon and may be distinct for givensubtypesuch as t(15;17) in M3 AML • Someleukemias do no fit to currentclassifications and aredescribed on thebasis of severalcytogeneticdefectssuch as genefusion, deletion, insertion etc. • In lymphoidtumorsantigen receptor generearrangementisearlierthanneoplastictransformation. Thus, tumorousgene products (immunoglobulinsorT-cellreceptors) areidenticalincontrast to normallymphocytesexpressingplethora of variousantigenreceptors. Itturned out to be of diagnosticvalue.

  14. Clinicalfeatures of leukemias • General: symptomsaremoreevidentinacutethaninchronicforms , but do not differ much inlymphoidvs. myeloidleukemias, • In chronictypestheonsetisusuallyinsidious: mild anemia, weakness, easyfatigue, weightloss, anorexia • Enlargement of spleen iscommoninbothtypesoften associated withleftupperquadrantpain, • Acuteleukemias manifest by abruptstormyonset: fever, infection, bleeding, bonepain, hepatosplenomegaly, cnsmanifestationssuch a vomiting, headache, nervepalsies.

  15. Chronic Leukemia • Often discovered because of an abnormal lab or an abnormal physical examination • Severe cytopenias characteristic of acute leukemia are seldom present at time of diagnosis

  16. Prognosisinleukemias • FairlygoodinprecursorB-cellleukemiasinchildhood • In chronicB-cellleukemias life expectancymay be comparable to normal one, providedthatthereis no cnsinvolvement • Acutemyeloidleukemiashaveusuallyunfavourableprognosis (15-30% remainfree of disease for 5 years), • In chronicmyelogenous leukemia supplementation of blood and properchemotherapyallowfro 4-5 yearssurvival, but theendisalmostalwaysfatal.

  17. Chroniclymphocytic leukemia/lymphoma (CLL/SLL-B)

  18. CLL-B: flowcytometry

  19. HairyCell Leukemia (HCL) • Clinical – pancytopenia, normal lymph nodes and splenomegaly • Incidence –mostly middle age males (2% of lymphomas) • Origin – mature B cells but with peculiar projections best seen in phase-contrast microscope. They are pan B, CD5-, CD25+, CD11c+, CD103+ • Infiltration of spleen, bone marrow and liver • Accompanying infections common often with atypical mycobacteria

  20. Spleen- hairycell leukemia

  21. FAB classification of acutemyelogenousleukemias • M0 AML – non-differentiated, incidence 2-3% • M1 AML – almostwithoutdifferentiation, 20% • M2 AML – myeloidmaturation of granuloc.30-40% • M3 AML – hypergranularpromyelocytes, 5-10% • M4 AML – cells of bothmyelocytic (min.20%) and monocyticorigin (<30%), 15-20% • M5 AML – Monoblasts (M5a) and monocytes (M5b), 10% • M6 AML – dysplasticerythroidprecursors and myeloblasts, 5% • M7 megakaryocytic leukemia – blasts of megakaryoc.lineagepredominate, 1% Number of blastsinall: < 20%

  22. AcuteMyelogenous Leukemia (AML) • Incidence:middleage, olderadults and children • Bonemarrow: normalcellsarereplaced but undifferentiatedblastswithsomemyeloidfeatures. Theyhaveblockedmaturation, increasedsurvival and thereplicationratelowerthannormalmyeloidprogenitors, • Genetic:severalchromosomalrearrangementsdisruptinggenesencodingtranscriptionfactorsneeded for normalmyeloidmaturation, • Lab findings: anemia, neutropenia, thrombocytopenia

  23. AcuteMyelogenous Leukemia (AML) - 2 • Flowcytometry:due to poorcellgranularityblastshaveverylowsitescatter. Theyusually show myeloid-specificsurfacemarkers (CD13, CD33) and markers of progenitorcells (CD34, CD117), but variousdeparturesfromtheabovearecommon, • Clinical:fatigue, spontaneousbleedings, infections, oftencaused by opportunisticpathogenssuch as fungiorPseudomonas. Organomegaly of liver, spleen, infiltration of skin, gingiva by normalmonocytesisoftenseen.

  24. Organomegaly

  25. Platelet Coagulation Petechiae, Purpura Hematoma, Joint bl.

  26. AML-M0 - Undifferentiated:

  27. AML-M2 - with maturation

  28. AML-M3 - Auer Rods

  29. AML-M4 - Myelomonocytic

  30. AML-M5 - Gum Hypertrophy:

  31. AML-M6 : Erythroleukemia

  32. PURE ERYTHROID LEUKEMIA

  33. AML-M7 : Megakaryocytic

  34. Chronicmyelogenous leukemia (CML) • Disease of adults(25 – 60 yrs), morecommoninwomen, • Bonemarrow– highlycellular, mainlymaturinggranulocyteprecursors, increasednumbers of megakaryocytes • Molecular– translocation of BCR gene (chromosome 9) to ABL gene (on chromosome 22) TheresultantBCR-ABLfusiongeneencodes protein withtyrosinekinaseactivity. So-called Philadelphia chromosomeseeninkaryotypingstudiesisthereflection of (9;22) translocation • Clinical – slow progressionup to 5 years, afterwardssome 50% of patients enter „acceleratedphase” withappearance of blasts, resemblingacute leukemia.

  35. BCR-ABL translocation Chronic Myelogenous Leukemia

  36. BCR – ABL GENES DISRUPTED IN THE t(9;22) CHROMOSOMAL ABNORMALITY

  37. CHRONIC MYELOID LEUKEMIA IN BLAST PHASE

  38. PolycythemiaVera • Cellorigin: multipotentmyeloidstemcell • Bonemarrow: increasedproduction of erythroid, granulocytic and megakaryocyticmaturingcelltypes • Blood: erythrocytosis, granulocytosis, thrombocytosis, increasedhematocrit and red cell mass • Clinical:insidiousonsetinlatemiddleage (above 60 yrs). Patientssufferfromheadache, dizziness, hypertension, gastrointestinalabnormalities, goutdue to high cellturnover. Thrombosis episodesarecommon. • Finalfate: either „spentphase” leading to marrowmyelofibrosiswithextramedullaryhematopoesisor terminal AML

  39. POLYCYTHEMIA VERA

  40. POLYCYTHEMIA VERA – CELLULAR PHASE

  41. POLYCYTHEMIA VERA-LATE PHASE

  42. MyelodysplasticSyndromes (MDS) • Definition:clonalcelldisordersmarked by maturationdefects, ineffectivehematopoiesis and increasedrisk of AML (10-40%) • Twodistincttypes: idiopatic (primary) MDS inolderpeoplewithinsidiouscourse. Oftendiscoveredincidentally on routinetesting. therapy-related MDS, due to previouschemo-orradiationtherapy, usually 2 to 8 yearsafter, • Bonemarrow: severaldistortedcells of myeloidlineageshowingvariousabnormalities. Myeloblastsmay be increased, but below 20%. Ifhigher – itisalready leukemia, • Survival:primary MDS-9-29 mo, therapy-related – 4 to 8 mo.

  43. Thankyou for yourpatience and perseverance!

More Related